Navigation Links
Highlights from the August 2008 issue of Ophthalmology
Date:8/1/2008

SAN FRANCISCO, CA The August issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes surprising findings on Asian ethnicity and macular degeneration and on nearsightedness in school children, as well as a study of successful treatments for ocular surface cancer.

Age-Related Macular Degeneration (AMD) in an Asian Population

AMD erodes and can eventually destroy the central vision needed for reading, driving, and other daily tasks. When AMD risk levels among racial and ethnic groups are compared, Caucasians are usually identified as at highest risk. Asians in particular have been assumed to have lower risk. Recently Ryo Kawasaki, MD, and colleagues compared the prevalence of early and late AMD in approximately 4,000 residents of Funagata, Japan, to the rate in white participants in the Australian Blue Mountains Eye Study (BMES); diagnostic definitions were identical in the two studies and age standardization enhanced data comparability. Importantly, the Funagata study is the first in a Japanese population to confirm a link between smoking and AMD prevalence.

The overall AMD prevalence rate in right eyes was 4.1 percent for the Funagata study, very close to the BMES rate of 4.4.percent. Prevalence of late AMD in men was also comparable for the two groups, 1.1 percent for Funagata participants and 1.2 percent for BMES, but was markedly different for the two groups of women: 0.3 percent and 2.1 percent, respectively. The authors note that these findings need to be confirmed by larger studies in Asian populations. Two earlier studies also found a higher prevalence of late AMD in Asian men, in contrast with most studies in Caucasians where rates are higher for women. The authors think a key reason may be that 36.8 percent of the Funagata men smoked, but only 2.8 percent of the women. In the BMES study, 14.4 percent of women were smokers. While many Asian men smoke, the habit is less socially acceptab
'/>"/>

Contact: Mary Wade
mwade@aao.org
415-447-0221
American Academy of Ophthalmology
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success
2. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
3. Cancer research highlights
4. Survey Highlights Physician Motivations for Working Locum Tenens Jobs
5. [video] WallSt.nets 3 Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: JSDA, GSPI, JACO, SGTI, HCPC
6. July 2008 Mayo Clinic Health Letter Highlights Bone Health, Causes of Swelling and Slimmed-Down Desserts
7. July 2008 Mayo Clinic Womens HealthSource Highlights Vitamin D, Savvy Use of Sunscreen and Gastrointestinal Upset and Celiac Disease
8. Research highlights problems of predicting birthweights in obese mothers
9. AVMA Collections Highlights Disaster Preparedness
10. Elsevier announces 2007 journal impact factor highlights
11. June 2008 Mayo Clinic Health Letter Highlights New MRI Scanning Technology, Obesity-Related Cancer, and Do-It-Yourself Massage

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...PRNewswire/ -- An exciting treatment gaining accep...latelet-rich plasma therapy (PRP), is showing stro...lant procedures, according to a prominent dental r...ntology . ,, James Rutkowski, DMD, PhD, repor... American Academy of Implant Dentistry that platel...
(Date:12/3/2009)...es rzteblatt International contains the first sci...the novel influenza A virus (H1N1/09) in the Germa...ic. Ralf Winzer and his coauthors from the Dsseldo...ata from a large clinical cohort of infected perso...770-6). Their medical-scientific article is accomp...
(Date:12/3/2009)... Deaths a day is still too many - stalled momentum... Atlanta, GA, Geneva, New York, NY a...Measles Initiative announced today that measles de...from an estimated 733 000 in 2000 to 164 000 in 20... resurgence in measles deaths if vaccination effor...
(Date:12/3/2009)...ra Pharma will be conducting a webinar on December...-counter and prescription treatments for chronic p... Plantation, FL (Vocus) December 3, 2009 -- ...company that is developing treatments for Adrenomy...S), has announced today that it will be hosting an...
(Date:12/3/2009)...f., Dec. 3 Osseon Therapeutics ann...vable bone cement delivery needle) and Osseoflex D...percutaneous vertebral augmentation received Canad... marketing and clinical use in Canada. ,, Canad... FDA approval in the United States, and allows for...
Breaking Medicine News(10 mins):Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain 3Health News:Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada 2
...rn to mothers who have low levels of foliate// in ...tudy. Folate is essential for fetal growth a... helping produce and maintain new cells. It is a B...und of folate, before conceiving and during the ea...
...ion for upgrading a medical college in Orissa.// ...allavbhai Patel Postgraduate Institute of Paediatr... and effectively contribute towards dispensation o...rsday by Japanese ambassador Yasukuni Enoki and Vi...
...th unhealthy foods could be used to treat// obesit...ersity of California, Irvine, and her colleagues c...eating strawberry ice cream as a child. She ...at suggested they had had an unpleasant experience...
...ip called Genotyper that can identify the genetic ... the doctors to treat patients effectively. D...n, the Genotyper is on its way to become fully por...fying the flu type is similar to genetic fingerpri...
...arean were less likely to conceive again //than th...new British study. Researchers led by Siladit...tain, followed women who had their first single ch...of mothers undergoing caesarean went on to have an...
...pes for a new drug to treat women with //low sexua...FDA) wants more studies to be done on the Intrinsa...ut what long-term side effects the drug may induce...ng with low desire. Though experts say femal...
Other Medicine News:Health News:Vitamin Supplements During Pregnancy to Boost Fetal Development 2Health News:Unpleasant Memory of Food could Be Used to Treat Obesity 2Health News:New Tools To Identify Flu Strains 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3
(Date:12/3/2009)... HELSINKI, December 3 After two...ccess in their field, Lightlake Therapeutics, expe...lecting and gene testing,subjects for a trial of a...,World Health Organisation has described as a glob..., A Phase II trial for the everyday treatment ...
(Date:12/2/2009)...YORK, Dec. 2 Reportlinker.com anno...le in its catalogue: ,, Cardiac Pacemakers - ...linker.com/p0164335/Cardiac-Pacemakers---A-World-M...itute a major segment in a rapidly expanding cardi...cemakers market is characterized by relatively mat...
(Date:12/2/2009)...O, Calif., Dec. 2 Varian... 25, 2009, Varian, Inc. filed with the U.S. Securi...Form 10-K for the fiscal year ended October 2, 200... Company,s web site at www.varianinc.com, by click..."10-K" in the table shown. Stockholders may recei...
Breaking Medicine Technology:Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 2Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 3Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 4Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 1Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 2Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 3Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 4Olympus Managed Health Care Receives Third Party Administrative License in State of Florida 52776 1Digitas Health Expands Adding Two Key Locations 13208 1Digitas Health Expands Adding Two Key Locations 13208 2Digitas Health Expands Adding Two Key Locations 13208 3Digitas Health Expands Adding Two Key Locations 13208 4
... Surface Treatment Maximizes,Endothelialization; R...Term,Dual Antiplatelet Therapy, WASHINGTON, Oct. ...Devices and Futuristic Therapies" session during t...eutics (TCT) scientific,symposium, sponsored by th...-month follow-up data from the ATLANTA Trial. The ...
...Cancer Populations Facilitates ...3 Rubicon Genomics, Inc. today,announced an agree...r The,Cancer Atlas Genome Project., Rubicon Genom...genomic,DNA from 3,000 tissue and blood samples fr...le Genome Amplification technology was judged best...
Other Medicine Technology:12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3
PVA, The Personal Vision Assistant
...elco general purpose incubators designed to provid...equired for the most demanding incubation applicat...cubators feature push-button temperature setpoint ...ilt-in over-temperature protection. Equally import...
...ecision Economy Incubators available in five diffe...on; capacities of 1.4 cu. Ft. (39 liters), 2.5 cu....ually important, Precision Economy Incubators comb...ature sensitivity, stability, and uniformity. As a...
40D Large
Medicine Products: